Annual Drug Patent Expirations for QSYMIA
Qsymia is a drug marketed by Vivus and is included in one NDA. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge.
QSYMIA drug price trends.
Drug patent litigation for QSYMIA.
This drug has thirty-eight patent family members in seventeen countries.
The generic ingredient in QSYMIA is phentermine hydrochloride; topiramate. One supplier is listed for this compound. Additional details are available on the phentermine hydrochloride; topiramate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published at New patent for VIVUS drug QSYMIA